Description
CD19 / Firefly Luciferase - CHO Recombinant Cell Line | 79714 | Gentaur US, UK & Europe Disrtribition
Category: CAR-T/Cell Line
Application: Useful as CD19-expressing target cells in co-culture assay with CD19-CAR-T cells, for both CD19-specific cell killing assay and cytokine production assay.
Background: B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be used as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkins Lymphoma (NHL), CLL and ALL.
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD19 protein (also known as B4 or CVID3, Genbank #NM_001770) and the firefly luciferase. Surface expression of CD19 was confirmed by flow cytometry.
Product Type: Cell Line
Shippement Condition: -80°C
